試す 金 - 無料
‘Innovations that serve a purpose, paired with a good go-to-market Strategy are attractive for VCs"
BioSpectrum Asia
|January 2023
Singapore’s health and biomedical landscape constitutes a vibrant pool of innovative medical technology, biotechnology and biopharmaceutical entrepreneurship.
Biomedical sciences industry is the fourth pillar of the country’s manufacturing economy and is extensively fostering local R&D and startups to boost innate innovations. In 2016, the Singapore government committed to a S$4 billion budget to drive research and commercialisation activities in the health and biomedical sciences sector. Further supporting the initiative, Enterprise Singapore Enterprise(SG), the statutory board of the Singapore Ministry of Trade and Industry plays a vital role in supporting local startup ecosystems. In an interaction with BioSpectrum Asia, Audrey Lok, Director of Healthcare and Biomedical, EnterpriseSG shared insights on its role in promoting Singapore as an Asia-Pacific hub for startups and innovations. Edited excerpts;
How conducive is Singapore's startup ecosystem for fostering bioscience initiatives and empowering entrepreneurship?
COVID-19 has rapidly accelerated the pace of medical innovation and transformation, and it comes as no surprise that we now have more investors and startups in this sector. As of 2021, 400 biomedical startups and SMEs in Singapore prioritise innovative solutions that address today’s healthcare needs or ones that address the pandemic. 1.3 billion in biomedical investments across 40 deals have been recorded in the same year.
A part of this success can be attributed to the thriving ecosystem built upon strong public-private partnerships. Our public healthcare clusters have enabled many healthcare and biomedical startups to embrace innovation, by tapping the clinical strengths and expertise of our healthcare system to refine, develop and testbed solutions. In fact, they have been supporting more than 100 industry engagements and facilitations every year. They are also critical partners who identify
このストーリーは、BioSpectrum Asia の January 2023 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
